Receptor antagonist

Dementia Drugs Market Predicted to Reach USD 19.7 Billion, Globally, by 2031 at 8.5% CAGR: Says Allied Market Research

Retrieved on: 
Monday, December 12, 2022

PORTLAND, Ore., Dec. 11, 2022 /PRNewswire/ -- Allied Market Research published a report, titled, "Dementia Drugs Market by Indication (Lewy Body Dementia, Parkinsons Disease Dementia, Alzheimers Disease, Vascular Dementia, Other Indications), by Drug Class (Cholinesterase Inhibitors, NMDA Antagonists and its Combination Drugs), by Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031". According to the report, the global dementia drugs industry generated $8.7 billion in 2021, and is anticipated to generate $19.7 billion by 2031, witnessing a CAGR of 8.5% from 2022 to 2031.

Key Points: 
  • However, strict government regulations related to product approval and high cost linked to R&D activity restrain the growth of dementia drugs industry.
  • Conversely, accelerated technological advancement in drug discovery techniques and high investment for drug development by the government are expected to offer lucrative opportunity for the dementia drugs market in future.
  • The outbreak of the Covid-19 pandemic had a positive impact on the global dementia drugs market, as it was reported that the pandemic caused a significant rise in the number of dementia patients.
  • Thus, increase in COVID-19 infection in patients with Alzheimer's disease increased the demand for dementia drugs during the pandemic.

Dementia Drugs Market Predicted to Reach USD 19.7 Billion, Globally, by 2031 at 8.5% CAGR: Says Allied Market Research

Retrieved on: 
Monday, December 12, 2022

PORTLAND, Ore., Dec. 11, 2022 /PRNewswire/ -- Allied Market Research published a report, titled, "Dementia Drugs Market by Indication (Lewy Body Dementia, Parkinsons Disease Dementia, Alzheimers Disease, Vascular Dementia, Other Indications), by Drug Class (Cholinesterase Inhibitors, NMDA Antagonists and its Combination Drugs), by Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031". According to the report, the global dementia drugs industry generated $8.7 billion in 2021, and is anticipated to generate $19.7 billion by 2031, witnessing a CAGR of 8.5% from 2022 to 2031.

Key Points: 
  • However, strict government regulations related to product approval and high cost linked to R&D activity restrain the growth of dementia drugs industry.
  • Conversely, accelerated technological advancement in drug discovery techniques and high investment for drug development by the government are expected to offer lucrative opportunity for the dementia drugs market in future.
  • The outbreak of the Covid-19 pandemic had a positive impact on the global dementia drugs market, as it was reported that the pandemic caused a significant rise in the number of dementia patients.
  • Thus, increase in COVID-19 infection in patients with Alzheimer's disease increased the demand for dementia drugs during the pandemic.

Harmony Biosciences Reports First Quarter 2021 Results and Business Updates

Retrieved on: 
Tuesday, May 11, 2021

The live and replayed webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/ .

Key Points: 
  • The live and replayed webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/ .
  • To participate in the live call by phone, dial (833) 614-1471 (domestic) or +1 (914) 987-7209 (international), and reference passcode 2269379.
  • We believe that the presentation of these measures provides important supplemental information to management and investors regarding our performance.
  • Reduce the dose of WAKIX by half.\nH1 receptor antagonists that cross the blood-brain barrier may reduce the effectiveness of WAKIX.

X4 Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 6, 2021

Retrieved on: 
Thursday, April 22, 2021

The conference call can be accessed by dialing (866) 721-7655 from\xc2\xa0the United States\xc2\xa0or (409) 216-0009 internationally, followed by the conference ID: 5658628.

Key Points: 
  • The conference call can be accessed by dialing (866) 721-7655 from\xc2\xa0the United States\xc2\xa0or (409) 216-0009 internationally, followed by the conference ID: 5658628.
  • The live webcast can be accessed on the investor relations section of X4 Pharmaceuticals\xe2\x80\x99 website at www.x4pharma.com .
  • The company\xe2\x80\x99s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy.
  • X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer.

Eisai: Discovery Research on AMPA-type Glutamate Receptor Antagonist Perampanel Honored With PSJ Award for Drug Research and Development 2021

Retrieved on: 
Friday, March 26, 2021

TOKYO, Mar 26, 2021 - (JCN Newswire) - Eisai Co., Ltd. has announced that drug discovery research conducted on perampanel (brand name: FYCOMPA, "perampanel"), the AMPA-type glutamate receptor antagonist discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development 2021 by the PSJ.

Key Points: 
  • TOKYO, Mar 26, 2021 - (JCN Newswire) - Eisai Co., Ltd. has announced that drug discovery research conducted on perampanel (brand name: FYCOMPA, "perampanel"), the AMPA-type glutamate receptor antagonist discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development 2021 by the PSJ.
  • The reasons for the selection of this discovery research for the award are outlined by the PSJ as follows.
  • Although glutamate receptors, which are responsible for neuronal excitation, have long been recognized as important drug discovery targets, they have not led to the creation of any drugs.
  • It has been demonstrated that perampanel is a selective, non-competitive AMPA receptor antagonist.

Sosei Heptares and Biohaven Enter Global Collaboration and License Agreement to Advance Novel Small-Molecule CGRP Antagonist Portfolio

Retrieved on: 
Tuesday, December 1, 2020

Under the agreement, Biohaven will receive exclusive global rights to develop, manufacture and commercialize a portfolio of novel, small-molecule CGRP receptor antagonists discovered by Sosei Heptares for the treatment of CGRP-mediated disorders.

Key Points: 
  • Under the agreement, Biohaven will receive exclusive global rights to develop, manufacture and commercialize a portfolio of novel, small-molecule CGRP receptor antagonists discovered by Sosei Heptares for the treatment of CGRP-mediated disorders.
  • In addition, Sosei Heptares will be eligible to receive tiered royalties on net sales of products resulting from the collaboration.
  • Vlad Coric, M.D., Chief Executive Officer of Biohaven, said: "We are excited to enter into this agreement with Sosei Heptares, a world leader in GPCR drug discovery.
  • Shinichi Tamura, Chairman, President and CEO of Sosei Heptares, commented:"We are delighted to enter this collaboration and license agreement with Biohaven for our portfolio of novel CGRP receptor antagonists.

Global Constipation Treatment Market (2020 to 2027) - by Therapeutic, Disease, Distribution Channel and Geography - ResearchAndMarkets.com

Retrieved on: 
Friday, October 30, 2020

The "Constipation Treatment Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Therapeutic; Disease; Distribution Channel, and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Constipation Treatment Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Therapeutic; Disease; Distribution Channel, and Geography" report has been added to ResearchAndMarkets.com's offering.
  • The report highlights trends prevailing in the market, and drivers and hindrances pertaining to the market growth.
  • The key factors driving the market growth include the rising prevalence of chronic constipation and increasing number of FDA approvals and drug developments drive the market growth.
  • Based on therapeutic, the constipation treatment market is segmented into laxatives, chloride channel activators, peripherally acting mu-opioid receptor antagonists, GC-C agonists, and 5-HT4 receptor agonists.

Preclinical Characterization of Novel B2-Receptor Antagonists Published in Frontiers in Pharmacology

Retrieved on: 
Thursday, July 30, 2020

ZUG, Switzerland, July 30, 2020 /PRNewswire/ -- Pharvaris , a clinical-stage company focused on the discovery and development of novel oral B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other B2R-receptor-mediated indications, has published data describing a novel class of small molecule bradykinin (BK) B2-receptor antagonists.

Key Points: 
  • ZUG, Switzerland, July 30, 2020 /PRNewswire/ -- Pharvaris , a clinical-stage company focused on the discovery and development of novel oral B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other B2R-receptor-mediated indications, has published data describing a novel class of small molecule bradykinin (BK) B2-receptor antagonists.
  • Preclinical data appear in a recent open-access article in Frontiers in Pharmacology demonstrating potency, mechanism, and properties consistent with oral bioavailability.
  • "PHA121 is the only oral B2-receptor antagonist in clinical development, currently in Phase 1 for the treatment of HAE.
  • Pharvaris is developing this novel small molecule for on-demand and prophylactic treatment of HAE and other bradykinin-mediated disease.

Brain receptor pulls open electrical gate like a puppet master

Retrieved on: 
Tuesday, June 30, 2020

Critical for brain development and function, the receptor converts chemical messages between cells into electrical signals within a neuron.

Key Points: 
  • Critical for brain development and function, the receptor converts chemical messages between cells into electrical signals within a neuron.
  • Unlocking the receptor's ion channel is like working a stringed puppetrock one part of the receptor and slender filaments pull open the channel's gate.
  • Understanding how the receptor works could lead to better treatments for Alzheimer's disease, depression, epilepsy, stroke, or schizophrenia.
  • But if an antagonist binds, the loop loosens so much that the LBD cannot pull open the gate.

BELLUS Health Reports First Quarter 2020 Financial Results and Business Highlights, and Provides Updates on BLU-5937

Retrieved on: 
Thursday, May 14, 2020

With a low-selectivity P2X3 antagonist therapy for chronic cough, an adverse effect on taste perception is a well-known and widely-documented tolerability issue.

Key Points: 
  • With a low-selectivity P2X3 antagonist therapy for chronic cough, an adverse effect on taste perception is a well-known and widely-documented tolerability issue.
  • BELLUS Health is exploring how P2X3 activation can contribute to irritation and pain, and whether inhibition of P2X3 receptors can help treat these afferent hypersensitization-related disorders.
  • BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders.
  • Consequently, actual future results and events may differ materially from the anticipated results and events expressed in the forward-looking statements.